Familial cases of atypical HUS were until recently associated with irreversible renal failure, including transplant recurrence.

Over the last 25 years, the understanding that there are causative genetic abnormalities in  complement proteins has transformed our understanding of this condition. And this has led to major therapeutic advances through the availability of eculizumab, an anti-C5 monoclonal antibody.

The UK has been at the cutting edge of this work, through the group in Newcastle led originally by Tim Goodship,   who was the first to describe the genetic complement defects, and now by David Kavanagh. (more soon)

Last Updated on May 24, 2023 by John Feehally